Why CRISPR Therapeutics AG Stock Lost Ground in September – Motley Fool
Simply Wall St |
Why CRISPR Therapeutics AG Stock Lost Ground in September
Motley Fool According to data from S&P Global Market Intelligence, shares of the gene-editing company CRISPR Therapeutics (NASDAQ:CRSP) dropped by 13.1% in September. CRISPR’s poor showing last month appears to stem from nothing more than investors … Next Capital Raising For CRISPR Therapeutics AG (CRSP)?Simply Wall St Street Analysts View On CRISPR Therapeutics AG (CRSP), China Life Insurance Company Limited (LFC)Post Analyst Crispr Therapeutics AG (CRSP) Expected to Announce Earnings of -$0.49 Per ShareBangaloreWeekly Highlight Press –Hot Stocks Point all 11 news articles » |
Cancer Therapy Advisor |
Arrival of CAR–T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs
Cancer Therapy Advisor CAR-T therapies like CTL019 are “living drugs” produced by removing patients’ T cells through leukapheresis, a type of apheresis specific to white blood cells, for genetic modification at an offsite lab, amplification, and reinfusion into the patient. |
BioPharma-Reporter.com |
Cut price Kymriah? ThermoGenesis thinks so with automated CAR–T tech
BioPharma-Reporter.com In August, Novartis made history when its product Kymriah (tisagenlecleucel) became the first chimeric antigen receptor (CAR) T-cell therapy to win US approval. The product is made by collecting a patient’s cells through apheresis at a specialised … |
|
Spark’s blindness gene therapy reviewed by US FDA
Reuters Oct 10 (Reuters) – Spark Therapeutics Inc’s experimental gene therapy for a rare inherited form of blindness is effective, though it is unclear whether the benefit lasts over time, according to a preliminary review by the U.S. Food and Drug Administration. |
Pulmonary Hypertension News |
IV-delivered Stem Cells Show Potential as Pulmonary Hypertension Therapy, Rat Study Shows
Pulmonary Hypertension News IV delivery of stem cells to rats with pulmonary arterial hypertension (PAH) reduced the animals’ harmful lung blood vessel remodeling and improved their blood flow, a study reports. Researchers said the implication was that the stem cells could be … |
BioPharma-Reporter.com |
Automated platform could slash the cost of CAR–T manufacturing, ThermoGenesis
BioPharma-Reporter.com In August, Novartis made history when its product Kymriah (tisagenlecleucel) became the first chimeric antigen receptor (CAR) T-cell therapy to win US approval. The product is made by collecting a patient’s cells through apheresis at a specialised … |
Genetic Literacy Project |
Inserting CRISPR machinery into human cells to fight Huntington’s and Lou Gehrig’s
Genetic Literacy Project Marine Corps veteran Thomas Corbett, 50, left, puts on a jacket with the help of his wife Doris Corbett, 51, March 5, 2014, at their home in Reidsville, N.C. Corbett was diagnosed with Amyotrophic lateral sclerosis (Lou Gehrig’s disease) in late 2011 … |